Search

Displaying results 2791 - 2800 of 4301 in total
  1. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

  2. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections.

  3. Drug

    Reteplase

    go.drugbank.com/drugs/DB00015
    ApprovedInvestigationalWithdrawn

    Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA.

  4. Drug

    Dalteparin

    go.drugbank.com/drugs/DB06779
    ApprovedInvestigational

    Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant.

  5. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa.

  6. Drug

    Zidovudine

    go.drugbank.com/drugs/DB00495
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group.

  7. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    It can only be administered intravenously but does not reach therapeutic concentrations in the central nervous system, eye and urine.

  8. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … previously developed COVID-19 monoclonal antibody treatments - including [bamlanivimab], [etesevimab], [casirivimab], and [imdevimab] - which have been found ineffective in the treatment of COVID-19 caused by

  9. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.

  10. Drug

    Metrizamide

    go.drugbank.com/drugs/DB01578
    Experimental

    Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.